Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 EUR | 0.00% |
|
-10.26% | +60.55% |
05-16 | GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024 | CI |
03-20 | Geneuro SA Announces Appointments of Board of Directors | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+60.55% | 55.4M | |
+40.80% | 53.67B | |
+34.07% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- GNRO Stock
- News GeNeuro SA
- GeNeuro Wins Regulatory Nod To Launch Mid-stage Study Of Post-COVID-19 Drug In Switzerland